Medarex To Start MDX010/Cancer Vaccine Combo Pivotal Trial For Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Medarex could submit a BLA for its metastatic melanoma treatment MDX-010 in combination with the cancer vaccine MDX-1379 under FDA’s Subpart E regulation as early as 2006, the firm says.